Cat. #161946
CACO-2-shPLCG1
Cat. #: 161946
Organism: Human
Tissue: Epithelial
Disease: Cancer
Model: Knockdown
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Marta Martins
Institute: Instituto de Medicina Molecular João Lobo Antunes
Primary Citation: Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600
Tool Details
*FOR RESEARCH USE ONLY
- Name: CACO-2-shPLCG1
- Parental cell: CACO-2
- Organism: Human
- Gender: Male
- Tissue: Epithelial
- Disease: Cancer
- Growth properties: A subcultivation ratio of 1:4 to 1:6 is recommended, 1 to 2 times per week.
- Model: Knockdown
- Crispr: No
- Description: CACO-2 cells were infected with PLCG1 shRNA lentiviral particles (Santa Cruz Biotechnology) for knocking down the gene. Selection of stable clones started 2 days after infection with 10 ?g/mL Puromycin.
- Biosafety level: 1
- Recommended controls: shRNA scrambled control
Target Details
- Target: PLCG1
- Target background: Phospholipase C gamma 1 is a ubiquitously expressed enzyme that catalyses the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction plays an important role in the intracellular transduction of receptor- and non-receptor- mediated tyrosine kinase activators, which has major implications in several cellular processes such as proliferation, migration, and angiogenesis. More recently, PLC?1 was shown involved in anti-EGFR therapy re...
Handling
- Format: Frozen
- Growth medium: DMEM with 10% FBS, 5% CO2
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
References
- Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600
